Lantheus Holdings Equity 2025

Lantheus Holdings Aktienanalyse

What does Lantheus Holdings do?

Lantheus Holdings Inc. is an American company in the field of medical technology and radiopharmaceuticals. It was founded in 1956 under the name New England Nuclear Corporation and has since built an impressive history. Initially, under the name New England Nuclear Corporation, the company focused on the manufacture of laboratory equipment and isotope technology. However, over time, the company has specialized in the development and production of radiopharmaceuticals and diagnostic imaging procedures. Today, the company offers a wide range of products that are used worldwide by medical professionals. Lantheus' business model is designed to provide solutions to the challenges of modern medical imaging. The company faces the challenges of obtaining drug approvals, developing medical devices, providing critical knowledge, and effectively penetrating the market. The company is divided into several divisions that focus on specific areas of medical imaging. These include the divisions of radiopharmaceuticals and medical imaging. Each of these divisions offers specialized products and services tailored to the needs of medical professionals and patients. Lantheus' radiopharmaceutical division specializes in the production of radiopharmaceuticals. These are used for the diagnosis and treatment of various diseases such as cancer, heart and kidney diseases, or thyroid diseases. The company specializes in the production of isotopes such as technetium-99m and rubidium-82, which are among the most commonly used radiopharmaceuticals. Lantheus' medical imaging division offers solutions for the diagnosis and examination of various diseases. This includes specialized devices and equipment used in clinics and diagnostic centers. These include devices for cardiology, neurology, or oncology, for example. One of Lantheus' most well-known products is the diagnostic agent Definity®, which is used for imaging of heart and vascular diseases. Definity® is an ultrasound contrast agent that contains inert gas bubbles that enhance the signal of ultrasound waves in the body. The agent is used to create detailed images of the heart and other organs in the body. Like many companies in the medical technology industry, Lantheus is currently facing numerous challenges, particularly regarding the long-standing debate about the cost of healthcare and access to high-quality medical imaging. Lantheus is responding to this with smart product development, particularly in the field of radiopharmaceuticals, critical knowledge, and effective market penetration. Overall, Lantheus Holdings Inc. has earned an excellent reputation in the medical technology industry. The company has tirelessly worked to create solutions for the challenges in medical imaging while keeping an eye on the latest scientific developments. Certainly, Lantheus will continue to play an important role in the development of radiopharmaceuticals and medical imaging solutions in the future. Lantheus Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Lantheus Holdings's Equity

Lantheus Holdings's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Lantheus Holdings's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Lantheus Holdings's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Lantheus Holdings's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Lantheus Holdings’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Lantheus Holdings stock

What is the equity of Lantheus Holdings this year?

Lantheus Holdings has equity of 815.89 M USD this year.

What was the equity of Lantheus Holdings compared to the previous year?

The equity of Lantheus Holdings has increased/decreased by 82.49% increased compared to the previous year.

What impact does a high equity have on investors of Lantheus Holdings?

A high equity is advantageous for investors of Lantheus Holdings as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Lantheus Holdings?

A low equity can be a risk for investors of Lantheus Holdings, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Lantheus Holdings affect the company?

An increase in equity of Lantheus Holdings can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Lantheus Holdings affect the company?

A reduction in equity of Lantheus Holdings can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Lantheus Holdings?

Some factors that can affect the equity of Lantheus Holdings include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Lantheus Holdings so important for investors?

The equity of Lantheus Holdings is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Lantheus Holdings take to change the equity?

To change equity, Lantheus Holdings can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Lantheus Holdings pay?

Over the past 12 months, Lantheus Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lantheus Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Lantheus Holdings?

The current dividend yield of Lantheus Holdings is .

When does Lantheus Holdings pay dividends?

Lantheus Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lantheus Holdings?

Lantheus Holdings paid dividends every year for the past 0 years.

What is the dividend of Lantheus Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lantheus Holdings located?

Lantheus Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lantheus Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lantheus Holdings from 1/14/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/14/2025.

When did Lantheus Holdings pay the last dividend?

The last dividend was paid out on 1/14/2025.

What was the dividend of Lantheus Holdings in the year 2024?

In the year 2024, Lantheus Holdings distributed 0 USD as dividends.

In which currency does Lantheus Holdings pay out the dividend?

The dividends of Lantheus Holdings are distributed in USD.